These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 18242898)

  • 1. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology.
    Teeranachaideekul V; Junyaprasert VB; Souto EB; Müller RH
    Int J Pharm; 2008 Apr; 354(1-2):227-34. PubMed ID: 18242898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability.
    Teeranachaideekul V; Müller RH; Junyaprasert VB
    Int J Pharm; 2007 Aug; 340(1-2):198-206. PubMed ID: 17482778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of Silymarin nanocrystals lyophilized power applying nanosuspension technology].
    Zhao X; Wang G; Zhang B; Li H; Nie Q; Zang C; Zhao X
    Zhongguo Zhong Yao Za Zhi; 2009 Jun; 34(12):1503-8. PubMed ID: 19777833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lutein nanocrystals as antioxidant formulation for oral and dermal delivery.
    Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
    Int J Pharm; 2011 Nov; 420(1):141-6. PubMed ID: 21884768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production and characterization of Hesperetin nanosuspensions for dermal delivery.
    Mishra PR; Al Shaal L; Müller RH; Keck CM
    Int J Pharm; 2009 Apr; 371(1-2):182-9. PubMed ID: 19162147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18.
    Pardeike J; Müller RH
    Int J Pharm; 2010 May; 391(1-2):322-9. PubMed ID: 20214969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients.
    Anhorn MG; Mahler HC; Langer K
    Int J Pharm; 2008 Nov; 363(1-2):162-9. PubMed ID: 18672043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of a chemically stable quercetin formulation using nanosuspension technology.
    Gao L; Liu G; Wang X; Liu F; Xu Y; Ma J
    Int J Pharm; 2011 Feb; 404(1-2):231-7. PubMed ID: 21093559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy.
    del Pozo-Rodríguez A; Solinís MA; Gascón AR; Pedraz JL
    Eur J Pharm Biopharm; 2009 Feb; 71(2):181-9. PubMed ID: 18940256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of surface-modified solid lipid nanocontainers formulated with a heterolipid-templated homolipid.
    Attama AA; Müller-Goymann CC
    Int J Pharm; 2007 Apr; 334(1-2):179-89. PubMed ID: 17140752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN).
    Helgason T; Awad TS; Kristbergsson K; McClements DJ; Weiss J
    J Colloid Interface Sci; 2009 Jun; 334(1):75-81. PubMed ID: 19380149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation.
    Freag MS; Elnaggar YS; Abdallah OY
    Int J Pharm; 2013 Sep; 454(1):462-71. PubMed ID: 23830765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying.
    Hu J; Ng WK; Dong Y; Shen S; Tan RB
    Int J Pharm; 2011 Feb; 404(1-2):198-204. PubMed ID: 21056643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.
    Lai F; Sinico C; Ennas G; Marongiu F; Marongiu G; Fadda AM
    Int J Pharm; 2009 May; 373(1-2):124-32. PubMed ID: 19429297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation mechanism of colloidal nanoparticles obtained from probucol/PVP/SDS ternary ground mixture.
    Pongpeerapat A; Wanawongthai C; Tozuka Y; Moribe K; Yamamoto K
    Int J Pharm; 2008 Mar; 352(1-2):309-16. PubMed ID: 18162340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular-level characterization of probucol nanocrystal in water by in situ solid-state NMR spectroscopy.
    Zhang J; Higashi K; Limwikrant W; Moribe K; Yamamoto K
    Int J Pharm; 2012 Feb; 423(2):571-6. PubMed ID: 22138607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines.
    Pardeike J; Strohmeier DM; Schrödl N; Voura C; Gruber M; Khinast JG; Zimmer A
    Int J Pharm; 2011 Nov; 420(1):93-100. PubMed ID: 21889582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injectable nimodipine-loaded nanoliposomes: preparation, lyophilization and characteristics.
    Guan T; Miao Y; Xu L; Yang S; Wang J; He H; Tang X; Cai C; Xu H
    Int J Pharm; 2011 May; 410(1-2):180-7. PubMed ID: 21414393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
    Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
    Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term stability of quercetin nanocrystals prepared by different methods.
    Kakran M; Shegokar R; Sahoo NG; Gohla S; Li L; Müller RH
    J Pharm Pharmacol; 2012 Oct; 64(10):1394-402. PubMed ID: 22943170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.